Inventors at the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are seeking a licensee or collaborator for positive allosteric modulators (PAMs) of the A₃ adenosine receptor (A₃AR), a known therapeutic target. These heterocyclic chemical compounds bind to a lipid-facing site on the receptor protein and contain elongated chains to enable bitopic anchoring in the cell membrane.

Competitive Advantages:

• Compounds contain features that help distinguish their desired (allosteric) and undesired (orthosteric) pharmacological effects on the A₃AR.
• Can be event and site-specific because adenosine is endogenously elevated in response to localized distress signals within the body

Potential Commercial Applications:

• Potential agents for treating inflammatory diseases, chronic pain, cancer, and non-alcoholic steatohepatitis (NASH).

If you are interested in learning more about this opportunity or contacting the licensing specialist, please view the abstract: A₃ Adenosine Receptor Positive Allosteric Modulators